•  Home
•  Products
•  Life Science
•  Antibodies
•  Anti-idiotypic Antibodies

Therapeutic antibodies have become a hot spot in the field of drug development for the treatment of cancers, autoimmune diseases, infectious diseases, and neurological diseases. As the field of therapeutic antibody development flourishes, there are opportunities for some biosimilars to enter the market. During drug development, pharmacokinetic (PK) and anti-drug antibody (ADA) assays are imperative for the evaluation of the safety and efficacy of new drug candidates or biosimilars. Pharmacokinetics is the study that describes and characterizes the absorption, distribution, metabolism, and excretion of a drug in human or animal body. ADAs are antibodies elicited in vivo to biotherapeutics, and they have an important role in the drug discovery process. The immunogenicity of potential new therapeutics can be evaluated by detecting and measuring ADAs.

Anti-idiotypic antibodies (Anti-IDs) are antibodies that bind to the variable region of another antibody. In PK/ADA assays, anti-idiotypic antibodies are a powerful tool to measure the concentration of antibody-based drug candidates in samples or serve as positive controls for anti-drug antibodies. Anti-idiotypic antibodies can be used in PK studies to detect and quantify antibody drug levels. In ELISA, anti-idiotypic antibodies are coated onto a plate and specifically bind to the antibody drug in samples for quantitative analysis of antibody drugs. ELISA is also a commonly used method for ADA detection, in which anti-idiotypic antibodies are used as positive controls or reference standards for qualitative ADA analysis in samples.

Product Range

Amerigo Scientific offers high-affinity anti-idiotypic antibodies to support immunogenicity and PK analysis in antibody drug development.

Application Examples